 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Tocagen
TOCA
Tocagen Reports Brain Cancer Trial Failure for Toca FC
conference date: August 8, 2019 press release only
discloure: I owned this stock briefly. Sold on 9/12/2019 after the trial failed.
| 2019 | |||
| Tocagen Q2 2019 |
|||
| Aug 8, 2019 | |||
Tocagen (TOCA) is a clinical-stage biotechnology company specializing in therapies for cancer.
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALNY |
| ALXN |
| AMAT |
| AMGN |
| BIIB |
| CLDX |
| CELG |
| EPZM |
| GILD |
| GLYC |
| INO |
| ISRG |
| MCHP |
| MYL. |
| PLX |
| REGN |
| SGEN |
| TTPH |
| VBLT |
| VSTM |
| XLNX |
| XLRN |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2019 William P. Meyers